C12N 2760/18434
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/18434 (Use of virus or viral component as vaccine) appears on 180 US grants and 221 published applications in this corpus.
Search patents in C12N- Granted patents
- 180
- Published applications
- 221
- Assignees
- 139
- Inventors
- 433
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 3 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 6 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 4 | 2 |
| 2002 | 1 | 6 |
| 2003 | 5 | 6 |
| 2004 | 3 | 4 |
| 2005 | 3 | 8 |
| 2006 | 0 | 2 |
| 2007 | 1 | 3 |
| 2008 | 4 | 6 |
| 2009 | 3 | 3 |
| 2010 | 3 | 7 |
| 2011 | 4 | 12 |
| 2012 | 4 | 7 |
| 2013 | 0 | 6 |
| 2014 | 5 | 10 |
| 2015 | 8 | 13 |
| 2016 | 7 | 13 |
| 2017 | 9 | 12 |
| 2018 | 12 | 23 |
| 2019 | 13 | 11 |
| 2020 | 17 | 18 |
| 2021 | 13 | 11 |
| 2022 | 10 | 6 |
| 2023 | 7 | 8 |
| 2024 | 7 | 10 |
| 2025 | 7 | 8 |
| 2026 | 7 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Measles virus vaccine expressing SARS-CoV-2 protein(s)16 Jun 2026US 12,653,881 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Targeted antigen delivery system and uses thereof26 May 2026US 12,636,378 B2SRI International
- Betacoronavirus mRNA vaccines19 May 2026US 12,629,412 B2ModernaTX, Inc.
- Transient expression of biologic materials17 Mar 2026US 12,576,041 B1
- Betacoronavirus mRNA vaccines17 Feb 2026US 12,551,734 B2ModernaTX, Inc.
- Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases6 Aug 2026US 2026/0224687 A1Centre National De La Recherche Scientifique
- Nucleic acid adjuvant16 Jul 2026US 2026/0201392 A1Aomori Yamada Gakuen Educational Corporation
- Anti-Viral Therapeutic Peptides, Conjugates, and Methods of Use Thereof14 May 2026US 2026/0131011 A1Decoy Therapeutics Inc.
- Betacoronavirus mrna vaccines23 Apr 2026US 2026/0108595 A1ModernaTX, Inc.
- Betacoronavirus mrna vaccines9 Apr 2026US 2026/0097110 A1ModernaTX, Inc.
Most cited
By later US patents
- Process for the production of virus vaccine116US 4,659,569 AKabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo · 1987
- Combination PIV3/hMPV RNA vaccines110US 10,064,934 B2ModernaTX, Inc. · 2018
- Vaccine stabilizer containing L-glutamic acid and L-arginine67US 4,337,242 AMerck & Co., Inc. · 1982
- Modified Morbillivirus V proteins65US 6,664,066 B2Wyeth Holdings Corporation · 2003
- Betacoronavirus mRNA vaccine46US 10,702,600 B1ModernaTX, Inc. · 2020